Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.42 | N/A | -1185.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.42 | N/A | -1185.71% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and emphasized the importance of their ongoing projects. They did not provide any forward guidance, indicating uncertainty about the near-term outlook.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and regulatory submissions.
Sarepta Therapeutics reported a significant loss per share, which was much worse than expected. The stock dropped over 26% in response, reflecting investor disappointment and concerns about the company's financial health. With no revenue reported and no guidance provided, uncertainty looms over the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025